Welcome to our dedicated page for Lisata Therapeutics SEC filings (Ticker: LSTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech like Lisata Therapeutics often means sorting through pages of scientific jargon on certepetide’s trial data and CendR Platform R&D costs. Our SEC filings hub tackles that problem head-on by pairing every document with AI-powered summaries, so you can pinpoint cash-runway figures, pivotal study milestones, and risk disclosures without wading through hundreds of footnotes.
Need the numbers behind the science? The annual report—listed here as the 10-K—details R&D spend on peptide delivery and outlines regulatory hurdles; our AI highlights each section, offering a "Lisata Therapeutics annual report 10-K simplified" view. Quarterly cash flow shifts appear in the 10-Q; search "Lisata Therapeutics quarterly earnings report 10-Q filing" and jump directly to liquidity tables. Material trial readouts and partnership announcements are filed on 8-Ks; our platform tags them "Lisata Therapeutics 8-K material events explained" for instant context.
Monitoring insider sentiment is equally easy. Real-time alerts for "Lisata Therapeutics insider trading Form 4 transactions" show executive stock moves moments after they hit EDGAR. A dedicated feed covers "Lisata Therapeutics Form 4 insider transactions real-time," while proxy statements clarify leadership pay—type "Lisata Therapeutics proxy statement executive compensation" to see our breakdown. From earnings-call exhibits to shelf registrations, every filing is updated the second it posts, then translated into plain English so you can focus on questions like "understanding Lisata Therapeutics SEC documents with AI" or compare data across forms in one click. Stock Titan turns complex biotech disclosures into actionable insights—saving hours and sharpening decisions.
Lisata Therapeutics (LSTA) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $4.249 million as operating expenses declined to $4.414 million from $5.336 million a year ago. Revenue was $0 in the quarter and $70 thousand year‑to‑date.
Liquidity and balance sheet: Cash and cash equivalents were $18.998 million, with total assets of $21.759 million and stockholders’ equity of $17.373 million as of September 30, 2025. The company states it has sufficient cash to meet funding requirements over the next 12 months and expects to seek additional financing by the end of 2026.
Operations and expenses: R&D was $1.959 million and G&A was $2.455 million in Q3. Year‑to‑date, R&D totaled $6.815 million and G&A $8.385 million. The company continued Phase 2 studies of certepetide and delayed certain Phase 3 readiness activities to manage cash.
Capital actions: Lisata raised $600,663 in net proceeds via its ATM during the nine months ended September 30, 2025 and sold $10.7 million of New Jersey NOLs for net proceeds of $871 thousand, recording a $962 thousand deferred income tax benefit.
Lisata Therapeutics (LSTA) furnished an 8-K announcing a press release with financial results for the third quarter ended September 30, 2025, and a corporate presentation. The materials are included as Exhibits 99.1 and 99.2.
These disclosures were provided under Regulation FD and are being furnished, not filed, and therefore are not subject to Section 18 of the Exchange Act nor incorporated by reference except as expressly stated.
Lisata Therapeutics furnished an investor slide presentation under Item 7.01 (Regulation FD). The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and will be used at investor and industry conferences.
The materials are expressly furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities. They are not incorporated by reference into Securities Act filings unless expressly stated.
Lisata Therapeutics entered into a worldwide non-exclusive license agreement with Catalent, Inc. to allow Catalent to use Lisata's iRGD cyclic peptide, certepetide, as an antibody drug conjugate (ADC) payload on Catalent's SMARTag4 ADC platform. Catalent will assume full responsibility for research, development and commercialization costs, while Lisata is eligible for pre-determined development milestone payments of up to
Lisata Therapeutics (Nasdaq:LSTA) filed an 8-K (Item 7.01 Regulation FD) announcing preliminary cohort B data from its Phase 2 ASCEND trial evaluating certepetide plus standard chemotherapy in metastatic pancreatic ductal adenocarcinoma. The company furnished a press release (Ex. 99.1) and investor slide deck (Ex. 99.2); the 8-K itself contains no numerical efficacy or safety results. Because the information is furnished, it is not deemed “filed” under the Exchange Act and carries no Section 18 liability. The disclosure is potentially material given certepetide’s status as the lead asset targeting a high-mortality cancer, yet the market impact depends on data contained only in the exhibits.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
